Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?

Trastuzumab has recently been introduced as a treatment for HER2-positive metastatic and/or unresectable gastric cancer (MUGC); however, compared with breast cancer, some issues concerning HER2 and trastuzumab therapy for gastric cancer remain unclear. A 74-year-old woman received trastuzumab-contai...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu Ishimine, Akira Goto, Yoshito Watanabe, Hidetaka Yajima, Suguru Nakagaki, Takashi Yabana, Takeya Adachi, Yoshihiro Kondo, Kiyoshi Kasai
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Case Reports in Gastrointestinal Medicine
Online Access:http://dx.doi.org/10.1155/2015/132030
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items